[Graft failure after allogeneic hematopoietic stem cell transplantation: Definition and risk factors].
Non-prise de greffe allogénique de cellules souches hématopoïétiques : définition et facteurs de risque identifiés.
Allografts
Blood Group Incompatibility
Disease Management
Graft Rejection
/ epidemiology
Graft vs Host Disease
/ complications
Hematologic Diseases
/ therapy
Hematopoietic Stem Cell Transplantation
/ mortality
Histocompatibility
Humans
Incidence
Neutropenia
/ etiology
Pancytopenia
/ etiology
Risk Factors
Transplantation Chimera
Allogeneic hematopoietic stem cell transplantation
Allogreffe de cellules souches hématopoïétiques
Graft failure
Infections
Non-prise de greffe
Rejection
Rejet
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
19
10
2018
revised:
02
03
2019
accepted:
07
03
2019
pubmed:
8
5
2019
medline:
25
6
2019
entrez:
8
5
2019
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation is the only curative therapy for numerous malignant and non-malignant haematological diseases. A sustained engraftment of the donor stem cells is essential for transplant success and overall outcome. Graft failure is a rare but severe event after allogeneic hematopoietic stem cell transplantation. While different risk factors such as underlying disease, graft source or HLA matching have been found to be consistently associated with graft failure, other factors such as ABO mismatch graft-versus-host disease prophylaxis or infections, particularly viral reactivations, are more controversial. In this article, we review the different factors associated with graft failure.
Identifiants
pubmed: 31060736
pii: S0007-4551(19)30160-2
doi: 10.1016/j.bulcan.2019.03.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
574-583Informations de copyright
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.